GlassScriptPhysician profile
Marilyn King
NPI 1740286707
$2,598.77
in general payments reported to CMS, 2019-2025
28 companies · $447 in 2025
The $447 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $127 · 2022: $289 · 2023: $836 · 2024: $899 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,500 · Long Term Medical Supply Or Device Loan: $500 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,499.87 |
| Long Term Medical Supply Or Device Loan | $499.98 |
| Education | $182.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $601.41 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $202.78 | 2021-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Pfizer INC. | $197.89 | 2022-2025 | |
| Seagen INC. | $154.27 | 2021-2023 | Adcetris, Tukysa |
| Daiichi Sankyo INC. | $145.69 | 2024-2025 | Enhertu |
| Aveo Pharmaceuticals, INC. | $128.32 | 2023-2025 | Fotivda |
| Astrazeneca Pharmaceuticals LP | $118.18 | 2023-2025 | |
| Janssen Biotech, INC. | $106.23 | 2022-2024 | Imbruvica, Darzalex, Erleada |
| Pharmacyclics LLC, An Abbvie Company | $103.70 | 2022-2023 | Imbruvica, Epkinly |
| Sanofi-Aventis U.S. LLC | $99.00 | 2023 | |
| Abbvie INC. | $94.02 | 2023-2025 | |
| Sobi, INC | $91.10 | 2023-2025 | |
| Glaxosmithkline, LLC. | $90.57 | 2023-2025 | Ojjaara, Shingrix |
| E.R. Squibb & Sons, L.L.C. | $58.16 | 2023-2024 | Opdualag, Opdivo |
| Lilly USA, LLC | $48.74 | 2023 | Verzenio, Retevmo, Jaypirca |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $46.54 | 2024-2025 | Xpovio |
| Bayer Healthcare Pharmaceuticals INC. | $42.32 | 2023-2025 | |
| Genzyme Corporation | $41.29 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $35.86 | 2025 | |
| Celgene Corporation | $33.59 | 2025 | Pomalyst |
| Stemline Therapeutics INC. | $27.16 | 2023 | Orserdu |
| Caris Mpi, INC. | $26.17 | 2025 | Mi Cancer Seek |
| Puma Biotechnology, INC. | $21.80 | 2023 | |
| Tolmar Pharmaceuticals, INC. | $20.65 | 2022 | |
| Astellas Pharma US INC | $18.75 | 2024 | Xospata |
| Ipsen Biopharmaceuticals, INC | $15.27 | 2021 | |
| Emd Serono, INC. | $15.18 | 2023 | Tepmetko |
| Coherus Oncology, INC. | $14.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marilyn King listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.